In an interview to Moneycontrol, Cipla#39;s Global Chief Financial Officer Kedar Upadhye expressed confidence that the company will outperform domestic formulation market and clock EBITDA margins of 22.5â23 percent for FY22.How to protect and exponentially Grow your investment portfolio during economic boom or bust, How learn stock market, How to earn money in stock market,earn money from home .
Cipla CFO says drug maker to outperform domestic market in FY22, Moderna vaccine import may take time
In an interview to Moneycontrol, Cipla#39;s Global Chief Financial Officer Kedar Upadhye expressed confidence that the company will outperform domestic formulation market and clock EBITDA margins of 22.5â23 percent for FY22.
Subscribe to:
Post Comments (Atom)
-
Market-men said the fall in gold prices at futures trade was mostly due to trimming of positions by participants.
-
Thirteen tier 2 and 3 cities register higher traffic in December than pre-COVID-19 levels.
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
No comments:
Post a Comment